Huzi Xu

990 total citations
16 papers, 473 citations indexed

About

Huzi Xu is a scholar working on Molecular Biology, Nephrology and Pathology and Forensic Medicine. According to data from OpenAlex, Huzi Xu has authored 16 papers receiving a total of 473 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 6 papers in Nephrology and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Huzi Xu's work include Acute Kidney Injury Research (3 papers), Chronic Kidney Disease and Diabetes (2 papers) and Ferroptosis and cancer prognosis (2 papers). Huzi Xu is often cited by papers focused on Acute Kidney Injury Research (3 papers), Chronic Kidney Disease and Diabetes (2 papers) and Ferroptosis and cancer prognosis (2 papers). Huzi Xu collaborates with scholars based in China and Saudi Arabia. Huzi Xu's co-authors include Ying Yao, Rui Zeng, Zhi Zhao, Han Zhu, Gang Xu, Zhizhi Hu, Jianliang Wu, Cheng Zhou, Zhangyin Ming and Yuxi Wang and has published in prestigious journals such as Nature Communications, Frontiers in Microbiology and Cell Death and Disease.

In The Last Decade

Huzi Xu

16 papers receiving 471 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Huzi Xu China 9 278 170 135 90 44 16 473
Han Zhu China 12 316 1.1× 170 1.0× 134 1.0× 148 1.6× 68 1.5× 19 618
Guoyu Dai China 9 170 0.6× 148 0.9× 128 0.9× 50 0.6× 23 0.5× 16 367
Meng Dou China 12 282 1.0× 126 0.7× 200 1.5× 69 0.8× 44 1.0× 27 499
Yuqi Xia China 13 232 0.8× 236 1.4× 110 0.8× 58 0.6× 36 0.8× 38 535
Guili Lian China 16 278 1.0× 193 1.1× 96 0.7× 34 0.4× 52 1.2× 38 577
Xiaomeng Feng China 12 245 0.9× 202 1.2× 158 1.2× 86 1.0× 33 0.8× 21 552
Qinglian Wang China 11 149 0.5× 55 0.3× 79 0.6× 102 1.1× 104 2.4× 27 423
Shuqin Mei China 13 233 0.8× 52 0.3× 103 0.8× 160 1.8× 60 1.4× 22 531
Xiaoju Li China 15 240 0.9× 64 0.4× 50 0.4× 55 0.6× 136 3.1× 46 546

Countries citing papers authored by Huzi Xu

Since Specialization
Citations

This map shows the geographic impact of Huzi Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Huzi Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Huzi Xu more than expected).

Fields of papers citing papers by Huzi Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Huzi Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Huzi Xu. The network helps show where Huzi Xu may publish in the future.

Co-authorship network of co-authors of Huzi Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Huzi Xu. A scholar is included among the top collaborators of Huzi Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Huzi Xu. Huzi Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Wang, Zheng, et al.. (2024). Increased Lymphatic Vessels: A Risk Factor for Severe Renal Function Loss in Obstructive Nephropathy Patients. International Journal of Medical Sciences. 21(12). 2305–2314. 1 indexed citations
2.
Li, Yinzheng, Zheng Wang, Huzi Xu, et al.. (2024). Targeting the transmembrane cytokine co-receptor neuropilin-1 in distal tubules improves renal injury and fibrosis. Nature Communications. 15(1). 5731–5731. 19 indexed citations
3.
4.
Zhao, Zhi, Guoli Li, Yuxi Wang, et al.. (2023). Cytoplasmic HMGB1 induces renal tubular ferroptosis after ischemia/reperfusion. International Immunopharmacology. 116. 109757–109757. 30 indexed citations
5.
Gao, Hui, Yinzheng Li, Jiqu Xu, et al.. (2023). Saccharomyces boulardii protects against murine experimental colitis by reshaping the gut microbiome and its metabolic profile. Frontiers in Microbiology. 14. 1204122–1204122. 10 indexed citations
6.
Deng, Xuan, Cheng Zhou, Yi Guo, et al.. (2021). Separated parabiont reveals the fate and lifespan of peripheral-derived immune cells in normal and ischaemia-induced injured kidneys. Open Biology. 11(6). 200340–200340. 4 indexed citations
7.
Cao, Chujin, Jianliang Wu, Huzi Xu, et al.. (2021). Combination of ultra-low dose rituximab and low dose tacrolimus versus tacrolimus alone in the treatment of non-responsive idiopathic membranous nephropathy: a Chinese retrospective cohort study.. American Journal of Translational Research. 13(7). 7622–7631. 6 indexed citations
8.
Gao, Hui, Yinzheng Li, Jie Sun, et al.. (2021). Saccharomyces boulardii Ameliorates Dextran Sulfate Sodium‐Induced Ulcerative Colitis in Mice by Regulating NF‐κB and Nrf2 Signaling Pathways. Oxidative Medicine and Cellular Longevity. 2021(1). 1622375–1622375. 28 indexed citations
9.
Zhao, Zhi, Jianliang Wu, Huzi Xu, et al.. (2020). XJB-5-131 inhibited ferroptosis in tubular epithelial cells after ischemia−reperfusion injury. Cell Death and Disease. 11(8). 629–629. 179 indexed citations
10.
11.
Deng, Xuan, Qian Yang, Yuxi Wang, et al.. (2019). Association of plasma macrophage colony-stimulating factor with cardiovascular morbidity and all-cause mortality in chronic hemodialysis patients. BMC Nephrology. 20(1). 321–321. 3 indexed citations
12.
Wang, M., Huzi Xu, Li Li, et al.. (2019). Compound α-keto acid tablet supplementation alleviates chronic kidney disease progression via inhibition of the NF-kB and MAPK pathways. Journal of Translational Medicine. 17(1). 28 indexed citations
13.
Zhu, Han, Meng Wang, Chengjun Zhao, et al.. (2018). GAG and collagen II attenuate glucocorticoid-induced osteoporosis by regulating NF-κB and MAPK signaling.. PubMed. 10(6). 1762–1772. 6 indexed citations
14.
Wang, Yuxi, Zhi Zhao, Weiqi Yang, et al.. (2018). Evaluation of the safety and tolerability of tamoxifen for ischemia-incited renal injury in mice.. PubMed. 10(7). 2184–2194. 2 indexed citations
15.
Zhu, Fengming, Huzi Xu, Zhi Zhao, et al.. (2017). Melatonin promoted renal regeneration in folic acid-induced acute kidney injury via inhibiting nucleocytoplasmic translocation of HMGB1 in tubular epithelial cells.. PubMed. 9(4). 1694–1707. 29 indexed citations
16.
Zhu, Fengming, Guangchang Pei, Zhizhi Hu, et al.. (2017). Adipose-derived mesenchymal stem cells employed exosomes to attenuate AKI-CKD transition through tubular epithelial cell dependent Sox9 activation. Oncotarget. 8(41). 70707–70726. 106 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Han Zhu Breakdown of academic impact, for papers by Guoyu Dai Breakdown of academic impact, for papers by Meng Dou Breakdown of academic impact, for papers by Yuqi Xia Breakdown of academic impact, for papers by Guili Lian Breakdown of academic impact, for papers by Xiaomeng Feng Breakdown of academic impact, for papers by Qinglian Wang Breakdown of academic impact, for papers by Shuqin Mei Breakdown of academic impact, for papers by Xiaoju Li
Rankless by CCL
2026